Crescent Grove Advisors LLC Acquires 1,595 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Crescent Grove Advisors LLC lifted its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,509 shares of the company’s stock after buying an additional 1,595 shares during the period. Crescent Grove Advisors LLC owned about 0.05% of ARK Genomic Revolution ETF worth $718,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in ARK Genomic Revolution ETF by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock valued at $75,655,000 after buying an additional 698,701 shares in the last quarter. Barclays PLC raised its stake in shares of ARK Genomic Revolution ETF by 252.7% during the third quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after acquiring an additional 204,283 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in ARK Genomic Revolution ETF by 2.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 166,281 shares of the company’s stock worth $3,904,000 after purchasing an additional 3,341 shares in the last quarter. PFM Health Sciences LP bought a new stake in ARK Genomic Revolution ETF during the 3rd quarter valued at $2,226,000. Finally, Quadrature Capital Ltd bought a new position in shares of ARK Genomic Revolution ETF during the 3rd quarter worth $1,970,000.

ARK Genomic Revolution ETF Trading Up 14.7 %

BATS ARKG opened at $27.09 on Friday. The firm’s 50 day simple moving average is $24.89 and its 200-day simple moving average is $25.14.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.